Han Zhong

Hanzhong Biomedical, a core subsidiary of Lepu Biopharma, is a Chinese biotechnology company specializing in the discovery and development of innovative oncology biologics. The company's flagship product, Pucotenlimab (HX008), is a humanized anti-PD-1 monoclonal antibody that has received regulatory approval in China for the treatment of MSI-H/dMMR solid tumors and melanoma. Hanzhong Biomedical is actively advancing a diverse clinical pipeline that explores Pucotenlimab in combination with chemotherapy, oncolytic viruses, and local treatments like transcatheter arterial chemoembolization (TACE). Leveraging its integrated R&D and manufacturing facilities in Taizhou, the company aims to address significant unmet needs in the oncology market through precision immunotherapy.